S-1/A: AEON Biopharma Eyes $357 Million Resale, Potential Capital from Warrants

AEON Biopharma files for a potential $357 million resale of common stock and warrants, while also eyeing potential capital from warrant exercises.

Summary

• AEON Biopharma has filed a registration statement for the resale of up to 69,182,155 shares of common stock and up to 3,988,952 private placement warrants.
• The filing includes the resale of shares issued in connection with a business combination, new money PIPE subscriptions, FPA funding amount PIPE subscriptions, and shares issuable upon conversion of convertible notes.
• It also covers shares reserved for issuance upon the exercise of options and settlement of restricted stock units, as well as shares issuable upon the exercise of outstanding warrants.
• The company may receive up to approximately $45.9 million from the cash exercise of private placement warrants, dependent on the trading price of the common stock.
• AEON intends to use any net proceeds from the exercise of such securities for general corporate and working capital purposes.
• The document also highlights the risks associated with the company's business operations, financial position, reliance on third parties, intellectual property, and government regulations.
• Management has concluded that uncertainties around the company's ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential for future growth and revenue generation, it also emphasizes the company's financial risks, dependence on third parties, and the competitive landscape. The going concern warning significantly lowers the sentiment score.

Positives

• AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in key markets.
• ABP-450 is manufactured in a facility approved by the FDA, Health Canada, and the EMA.
• The company has a management team with experience in biopharmaceutical and botulinum toxin development.
• The company is pursuing an original BLA that contemplates exclusively therapeutic uses of ABP-450.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• The company's future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450.
• The company faces significant competition in the pharmaceutical industry.
• The company relies on a third party, Daewoong, to manufacture ABP-450.
• The company's management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.

Risks

• The company may not obtain regulatory approvals for ABP-450 in a timely manner or at all.
• Clinical product development involves a lengthy, expensive, and uncertain process.
• ABP-450 may fail to achieve market acceptance even if it receives regulatory approval.
• The company relies on the Daewoong Agreement for exclusive rights to commercialize and distribute ABP-450.
• The company may be subject to claims of intellectual property infringement.
• Sales of a substantial number of the company's securities in the public market by existing securityholders could cause the price of the common stock and warrants to fall.
• The company will require additional capital, which may result in restrictions on operations or substantial dilution to stockholders.

Future Outlook

The company expects to expend substantial resources for the foreseeable future to complete the development of and seek regulatory approval for ABP-450, identify future potential therapeutic applications for ABP-450, and establish sales and marketing capabilities to commercialize ABP-450 across any approved indications.

Management Comments

• Management has concluded that uncertainties around the company's ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.
• The company expects to have sufficient cash to fund its operating plan through June 2024, including $15 million of committed financing related to the issuance of certain Convertible Notes with Daewoong.

Industry Context

The document provides context on the competitive landscape of the pharmaceutical industry, particularly in the botulinum toxin market, highlighting key players like Allergan, Ipsen, and Revance, and their respective products. It also touches upon the regulatory environment and the potential impact of healthcare reforms on the company's ability to obtain regulatory clearance and market its products.

Comparison to Industry Standards

• The document mentions Botox, Dysport, and Xeomin as the primary competitors for ABP-450 in the injectable botulinum toxin pharmaceutical market for therapeutic use.
• It notes that many competitors have greater financial resources, enabling them to make larger R&D, marketing, and promotion investments.
• The document also discusses the potential impact of biosimilars on ABP-450's market exclusivity, referencing the Biologics Price Competition and Innovation Act of 2009.
• Revance's daxibotulinumtoxinA is mentioned as a potential competitor with a longer duration of effect, which may compare favorably to ABP-450.

Legal Proceedings

• Odeon Capital Group LLC filed a lawsuit against the company in the Supreme Court of the State of New York, alleging failure to pay a deferred underwriting fee of $1.25 million.

Related Party Transactions

• The document details several related party transactions, including convertible note subscriptions, services agreements, and the Medytox settlement agreement.
• These transactions involve entities affiliated with major stockholders, directors, and officers of the company.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the exercise of warrants.
• The company's ability to continue as a going concern impacts all stakeholders, including employees, suppliers, and creditors.
• The success of ABP-450 will directly affect patients suffering from migraine, cervical dystonia, and gastroparesis.

Next Steps

• The company expects to announce an interim readout of topline data related to the chronic cohort of its Phase 2 migraine study in the second quarter of 2024, with full topline data to be released in the third quarter of 2024.
• The company plans to request an end-of-phase 2 meeting with the FDA with respect to the episodic cohort to discuss the protocol and study design for Phase 3, and the meeting is expected to take place in the first half of 2024.
• The company is in discussions with the FDA regarding the design of its Phase 3 study in cervical dystonia, which it expects to commence based on the availability of capital resources.
• The company expects to initiate a Phase 2a clinical study in 2024 to study the safety and efficacy of injecting a therapeutic dose of ABP-450 through a standard sclerotherapy needle into the pylorus and pyloric sphincter region for gastroparesis, subject to the availability of capital resources.

Key Dates

Keywords

AEON Biopharma, ABP-450, Resale, Warrants, Common Stock, Registration Statement, Convertible Notes, Daewoong, PIPE, Clinical Trials, Regulatory Approval, Financial Risk